| Preoperative assessments | | | | | | | |
| Johnson et al/2012[10] | 53.9, 55/36 | WAIS-R, WAIS-III, HVLT-R questionnaire | NA | Executive function and attention are cognitive domains related to prognosis of GBM | 9 year | retrospective study | cognitive function |
| Rambeau et al/2018 [11] | 78 (70-93), 25/41 | MMSE (13) | MoCA (44) | MoCA seems to be more relevant to screen cognitive impairment | 1 year | RCT | cognitive function |
| Fiorentino et al/2012 [12] | 72 (65-81), 17/18 | RTCHT (35) | NA | Comorbidity assessments is an appropriate tool for predicting prognosis of elderly patients with GBM | 6 year | single-arm clinical trial | comorbidity |
| Ening et al/2015 [13] | 62 (15-84), 117/116 | NA | NA | Besides old age and low KPS score, higher CCI is significantly associated with poor OS and PFS in dismal GBM, hence decides patient stratification | 5 year | retrospective review | comorbidity |
| Cloney et al/2015 [14] | no less than 65, NA | surgical resection | biopsy | Frailer elderly GBM patients are less likely to undergo surgical resection, have longer hospital stay, more complications, and less OS | 12 year | retrospective study | frailty |
| Peters et al/2014 [15] | mean 50, 161/76 | NA | NA | Greater degree of fatigue was associated with poor survival in recurrent HGG patients, which shows fatigue is an independent predicator for OS rather than QoL | 2 year | prospective cohort study | fatigue and QoL |
| Borg et al/2011 [16] | mean 60.1, 419/266 | NA | NA | GBM patients with pre-operative hypoalbuminaemia status have less post-operative OS than normal albumin | 10 year | retrospective study | lab indicators |
| He et al/2017 [17] | 44 (5-78), 197/129 | surgery (some received aggressive adjuvant treatment) | NA | Newly diagnosed HGG patients with elevated fibrinogen level and decreased albumin levels have more risk of tumor progression and death | 2 year | single-arm clinical trial | lab indicators |
| Preradiotherapy assessments | | | | | | | |
| VanderWalde et al/2017 [49] | 72.5 (65-92), 24/22 | NA | NA | Cancer patients failed to receive pre-treatment are more likely to have low health-related quality of life. | 2 year | prospective cohort study | health-related quality of life |
| Antonio et al/2018 [50] | 79.5 (75-87), 76/9 | NA | NA | Fit NSCLC patients have longer mOS than medium-fit; patients with higher VES-13 will have shorter mOS and high risk of G3-4 toxicity | 8 year | prospective cohort study | geriatric assessments |
| Pottel et al/2014 [51] | 72 (65-86), 86/14 | NA | NA | CGA helps to identify the evolution of health problems and is indicative of quality of life in patients with head and neck carcinoma | 2 year | prospective cohort study | geriatric assessments |
| Gielda et al/2011 [52] | 64 (30-84), 22/32 | NA | NA | Weight decrease strongly correlates with declined OS/PFS of NSCLC patients. Weight change during treatment should be treated as potential predicator | 11 year | prospective cohort study | nutritional status |
| Fiorentino et al/2012 [12] | more than 65, 17/18 | NA | NA | Elderly GBM patients with lower CCI score will have a longer OS than those with higher | 6 year | prospective cohort study | comorbidity |
| Chaichana et al/2011 [53] | older than 65, 67/66 | NA | NA | KPS score less than 80, motor deficit, language deficit, cognitive deficit are independently associated with decreased OS of elderly GBM patients | 10 year | retrospective study | KPS score, motor, language cognitive function |
| Prechemotherapy assessments | | | | | | | |
| Wick et al/2017[47] | 57.7 (21.2-82.3), 265/172 | lomustine plus bevacizumab (288) | lomustine
alone (149) | Despite somewhat prolonged PFS, lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in glioblastoma patients. The combined therapy affected neither health related quality of life nor neurocognitive function. The MGMT status is prognostic | 3 year | RCT | cognitive functiion |
| Aparicio et al/2013[59] | 80 (75-91), 66/57 | fluorouracil (62) | fluorouracil with irinotecan (61) | Cognitive function and autonomy impairment assessed by MMSE, IADL, MMSE are predictive of severe toxicity or unexpected hospitalization of elderly metastatic colorectal cancer patients | 7 year | RCT | cognitive function, autonomy impairment |
| Aaldriks et al/2011[60] | 77 (71-92), 90/112 | NA | NA | Inferior MNA and MMSE scores increase the probability of elderly cancer patients not to complete hemotherapy | 3 year | prospective cohort study | MNA, MMSE |